Oncology Phase 1 Deal Benchmarks — Europe (2026)

Median upfront of $22M with total deal values reaching $319M in Europe territory.

Median Upfront

$22M

Total Deal Value

$220M

Royalty Range

5.7%–9.9%

Territory Multiplier

0.25x

Understanding Oncology Deal Benchmarks at Phase 1

Phase 1 Oncology licensing deals in Europe territory command a median upfront payment of $22M, with values ranging from $10M at the low end to $34M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $121M to $319M, with a median of $220M. Royalty rates for oncology assets at this stage typically fall between 5.7% and 9.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2024	Hansoh Pharmaceutical	Merck	$118M	$1.9B	licensing
2023	CSPC Pharmaceutical	Elevar Therapeutics	$60M	$700M	licensing
2024	Innovent Biologics	Sanofi	$300M	$2.3B	licensing
2024	Menarini Group	N/A (EU commercialization)	$0M	$800M	licensing
2024	Hengrui Medicine	Merck	$160M	$1.6B	licensing
2024	Kelun-Biotech	AbbVie	$200M	$1.4B	licensing
2024	Ipsen	Exelixis	$0M	$950M	licensing
2023	Epizyme	Ipsen	$247M	$247M	licensing

PRO

See All Comparable Deals

View 8 comparable Oncology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 1 Oncology deals in Europe territory?

The median upfront payment for Phase 1 Oncology licensing deals in Europe territory is $22M, based on our analysis of comparable transactions. Values range from $10M for early-stage or less differentiated assets up to $34M for premium programs with strong clinical data or first-in-class mechanisms.

How does Europe territory affect Oncology deal value?

Europe rights carry a 0.25x multiplier relative to base deal economics. This means europe oncology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 1 Oncology licensing?

Royalty rates for Phase 1 oncology assets typically range from 5.7% to 9.9% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$8M upfront

Oncology · Preclinical · Europe

$64M upfront

Oncology · Phase 2 · Europe

$180M upfront

Oncology · Phase 3 · Europe

$519M upfront

Oncology · Approved · Europe

$19M upfront

Neurology/CNS · Phase 1 · Europe

$41M upfront

Immunology · Phase 1 · Europe

$57M upfront

Metabolic/Obesity · Phase 1 · Europe

$90M upfront

Oncology · Phase 1 · Global

Explore More

All Oncology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Oncology · Phase 1

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Oncology Phase 1 Deal Benchmarks — Europe (2026). Retrieved from https://calculator.ambrosiaventures.co/data/oncology-phase-1-deals-europe

HTML

<a href="https://calculator.ambrosiaventures.co/data/oncology-phase-1-deals-europe">Oncology Phase 1 Deal Benchmarks — Europe (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$10M	$22M	$34M
Total Deal Value	$121M	$220M	$319M
Royalty Rate	5.7%	—	9.9%